ABCB1 and hyperlipidemia: Based on the facts that nalbuphine is a P-glycoprotein substrate and that hyperlipidemia was shown to reduce P-glycoprotein activity, it is plausible that nalbuphine brain entry, and consequently its pharmacological effects, could be enhanced in hyperlipidemic patients.